- Conditions
- Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy, Partial Hepatectomy
- Drug · Procedure
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 367
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 253 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1273–1296
of 1,938
matching trials from the local directory fallback.
- Conditions
- Breast Screening
- Interventions
- Digital Mammography, Digital Tomosynthesis Mammography, Laboratory Biomarker Analysis
- Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 45 Years to 74 Years · Female only
- Enrollment
- 108,508 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2029
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 107 more
- Conditions
- Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus, Hypertension, Vascular Diseases
- Interventions
- Renal Denervation (Symplicity Spyral™)
- Device
- Lead sponsor
- Medtronic Vascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Ripretinib, Sunitinib
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 43
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 38 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 34
- States / cities
- Anniston, Alabama • Cullman, Alabama • Anaheim, California + 30 more
- Conditions
- Pulmonary Hypertension Associated With HFpEF
- Interventions
- Placebo, TNX-103
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 45
- States / cities
- Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- MTX-463, Placebo
- Biological · Other
- Lead sponsor
- Mediar Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 19 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- HA Chemotherapy
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pleural Malignant Mesothelioma
- Interventions
- Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
- Conditions
- CLL
- Interventions
- Obinutuzumab, Sonrotoclax, Venetoclax, Zanubrutinib
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 652 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 40
- States / cities
- Anchorage, Alaska • Duarte, California • La Jolla, California + 35 more
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- Bevacizumab, Cholecalciferol, Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Dietary Supplement · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1027
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 676 more
- Conditions
- Diabetes, Type 2, Obesity, Overweight, Overweight and/or Obesity, Type 2 Diabetes
- Interventions
- PF-08653944, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 55
- States / cities
- Anaheim, California • Canoga Park, California • Cerritos, California + 45 more
- Conditions
- Obesity and Overweight
- Interventions
- MET097, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 37
- States / cities
- Scottsdale, Arizona • Canoga Park, California • Oxnard, California + 33 more
- Conditions
- APOL1-Mediated Kidney Disease
- Interventions
- APOL1 Genotyping Clinical Trial Assay, AZD2373-Arm 1, AZD2373-Arm 2, Placebo
- Device · Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 86
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more
- Conditions
- Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
- Interventions
- Cisplatin (for the first 8, 21-day, cycles), Durvalumab (for the first 8, 21-day, cycles), Durvalumab (starting from cycle 9), Gemcitabine (for the first 8, 21-day, cycles), Ivosidenib, Ivosidenib Recommended Combination Dose (RCD)
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Los Alamitos, California • Los Angeles, California • Chicago, Illinois + 5 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
- Interventions
- Bevacizumab, Carboplatin, Cetuximab, Cisplatin, Fluorouracil, Gemcitabine, Leucovorin, Nab-paclitaxel, Oxaliplatin, PF-07934040, Paclitaxel, Pembrolizumab, Sasanlimab, pemetrexed
- Combination Product · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Placebo, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 130
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
- Interventions
- Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Months
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 193
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more
- Conditions
- COVID-19, SARS-CoV2
- Interventions
- COMIRNATY®, VXA-CoV2-3.1, VXA-CoV2-3.3
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 145
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 815 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
- Conditions
- Tachycardia, Ventricular Arrhythmia
- Interventions
- Defibrillation using EV-ICD
- Device
- Lead sponsor
- Medtronic
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2037
- U.S. locations
- 57
- States / cities
- Huntington Park, California • Redwood City, California • San Diego, California + 45 more
- Conditions
- Relapsed or Refractory Follicular Lymphoma
- Interventions
- Lenalidomide, Mosunetuzumab, Rituximab, Tociluzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 17
- States / cities
- Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more
- Conditions
- Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Carboplatin, Comprehensive Geriatric Assessment, Pembrolizumab, Pemetrexed, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 505
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 318 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Intravitreal Ranibizumab 0.5 mg Injection, PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Ranibizumab refill exchange
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 89
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 79 more